← Leaderboards
Angelina V Vaseva
University Of Texas Hlth Science Center
$1,395,448
Attributed
$1,395,448
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $356.6K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,395,448 · 1
By mechanism
R37$1,395,448 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Peter J Houghton$32,798,876
- Chul Soo Ha$714,399
- Sandeep Burma$8,062,293
- Raushan Kurmasheva$2,024,146
- Feng-Chun Yang$5,883,606
Others in their field
Other Rising Stars on “Embryonal Rhabdomyosarcoma”
- Genevieve Claire Kendall · Research Inst Nationwide Children'S Hosp$1,673,106
- Anand G Patel · St. Jude Children'S Research Hospital$290,017
- Bradley Stevens · St. Jude Children'S Research Hospital Graduate School Of Biomedical Sciences, Llc$96,512
- Grace Elizabeth Adkins · St. Jude Children'S Research Hospital Graduate School Of Biomedical Sciences, Llc$48,538
Research focus
Embryonal RhabdomyosarcomaCell Cycle ArrestApoptosisChemoradiationChemotherapeutic AgentChemotherapyCell LineChemotherapy-Oncologic ProcedureChildClassificationClinical ProtocolsClinical TrialsClinical Trials DesignClonal EvolutionCodon NucleotidesChemotherapy And/Or RadiationCombined Modality TherapyDiagnosisDna DamageDna RepairDna SequencingDoseDown-RegulationEpigenomics
Grant awards (5)
Improving Therapeutic Approaches for RAS-driven Rhabdomyosarcoma$356,579
R37 · FY2025 · CA · contact PI
Improving Therapeutic Approaches for RAS-driven Rhabdomyosarcoma$195,227
R37 · FY2024 · CA · contact PI
Improving Therapeutic Approaches for RAS-driven Embryonal Rhabdomyosarcoma$141,608
R37 · FY2024 · CA · contact PI
Improving Therapeutic Approaches for RAS-driven Embryonal Rhabdomyosarcoma$347,471
R37 · FY2023 · CA · contact PI
Improving Therapeutic Approaches for RAS-driven Embryonal Rhabdomyosarcoma$354,563
R37 · FY2022 · CA · contact PI